Clinical Trials Logo

Clinical Trial Summary

1. Evaluate the relationship of RDW and severity and mortality in patients with neonatal sepsis .

2. Using RDW as a simple, inexpensive, applicable and rapid test to detect prognosis of neonatal sepsis .


Clinical Trial Description

Sepsis is defined as a life-threatening condition caused by a dysregulated host response to infection. Sepsis is responsible for approximately 45% of neonatal emergencies and is a leading cause of neonatal mortality and morbidity, accounting for 14% of deaths in that age group.

The early symptoms and signs of neonatal sepsis are usually mild and nonspecific but can rapidly progress to septic shock, disseminated intravascular coagulation(DIC), and death. It is therefore of paramount importance to find a tool for prediction of infants who are more likely to experience a worse clinical outcome so that closer monitoring and more aggressive treatment would be offered to them.

Early-onset sepsis (EOS) is usually due to transplacental, ascending, or intrapartum transmission in the perinatal period shortly before or during birth, up to postnatal (PN) 7 days. Late-onset sepsis (LOS) is acquired by horizontal transmission in the home, hospital, or in the community after PN day.

Timely diagnosis and prompt institution of antimicrobial therapy are essential in order to mitigate the high case fatality and to avert morbidity associated with late-onset neonatal sepsis. In the latest years, biochemical markers are important in research areas in neonatal infections. Inflammatory cascade as response to an infection comprise many elevated markers, frequently used for diagnosis and monitoring of sepsis.

Numerous molecules have been studied as potentially useful prognostic markers in neonatal sepsis. These include C-reactive protein (CRP), procalcitonin, IL-6, IL-8, CD64, and soluble E- selectin.

The red cell distribution width (RDW) is a marker, which has been studied in neonatal sepsis. The RDW is a measure of variability of red blood cells in size (anisocytosis) and is routinely evaluated as a part of complete blood count. The RDW may be elevated in conditions of ineffective production, or increased destruction of red blood cells, which commonly occur in inflammatory or infectious situations.

Red cell distribution width has been classically used as a screening index for iron deficiency anemia. However, a growing body of evidence indicates that this simple marker can have a role in predicting adverse outcome in sepsis as well as in diverse clinical situations, including coronary artery disease, heart failure,acute pancreatitis, malignancy, infective endocarditis, peritoneal dialysis, and in critically ill children in general.

The pathophysiology of the elevation of RDW in these patients is not well known, but it has been reported that elevated RDW is associated with inflammatory markers such as C-reactive protein (CRP), erythrocyte sedimentation rate, interleukin-6 and tumor necrosis factor-alpha. Proinflammatory cytokines of sepsis have been shown to suppress the maturation of red blood cells (RBC) and decrease the half-life of RBCs, resulting in the elevation of RDW values Most previous studies investigating the prognostic value of RDW were conducted on adult patients, and similar studies in neonatal sepsis are rare and small. The objective of the present research is to investigate the prognostic role of this routinely available marker in full term neonates with sepsis and to compare it with other traditional prognostic biomarkers.

The prognostic potential of RDW is of particular interest because it is routinely included in the automated complete blood count (CBC) analyses in hospitalized patients and thus available and no additional cost for clinicians. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03403062
Study type Observational
Source Assiut University
Contact Mariam N Gamil, Resident
Phone 00201285508913
Email mnga_15@yahoo.com
Status Not yet recruiting
Phase
Start date February 2019
Completion date February 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05692128 - Frequency and Severity of Thrombocytopenia in Neonatal Sepsis
Completed NCT00942084 - A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo) Phase 1
Completed NCT06002295 - A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns Phase 2
Not yet recruiting NCT05114057 - Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI N/A
Recruiting NCT04528251 - Comparison of the Effectiveness of Two Different Antibiotic Regimens of the Treatment of Pregnant Women With Preterm Rupture of Membranes
Active, not recruiting NCT03871491 - Azithromycin-Prevention in Labor Use Study (A-PLUS) Phase 3
Completed NCT03746743 - Severity Index of Neonatal Septicemia Using Score for Neonatal Acute Physiology (SNAP) II
Completed NCT02386592 - Prevention of Nosocomial Bacteremia Among Zambian Neonates N/A
Not yet recruiting NCT06113653 - Outcomes and Predictors of Mortality Among Preterm Infants With Neonatal Sepsis
Completed NCT03199547 - Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death Phase 3
Completed NCT02147327 - Effects of Cord Blood 25-hydroxy-vitamin D Level on Early Neonatal Morbidities N/A
Completed NCT01005589 - CD64 Measurement in Neonatal Infection and Necrotising Enterocolitis N/A
Completed NCT00866567 - Defects in Opsonophagocytosis in Premature Infants N/A
Completed NCT02281890 - Neurodevelopmental Outcomes After Suspected or Proven Sepsis: Secondary Analysis of INIS Trial Database N/A
Suspended NCT05156333 - Probiotics and GBS Colonization in Pregnancy N/A
Recruiting NCT05127070 - Evaluating the NeoTree in Malawi and Zimbabwe
Completed NCT03755635 - Neonatal Sepsis at Neonatal Intensive Care Units in Ghana N/A
Completed NCT03247920 - Reduction of Intravenous Antibiotics In Neonates Phase 4
Completed NCT03295162 - Effects of Melatonin as a Novel Antioxidant and Free Radicals Scavenger in Neonatal Sepsis Phase 1/Phase 2
Completed NCT02954926 - Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis Phase 3